DelveInsight’s “Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Triple Negative Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Triple Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Triple Negative Breast Cancer Market Forecast

Some of the key facts of the Triple Negative Breast Cancer Market Report: 

• The Triple Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In June 2023, Gilead Sciences awarded the first “Towards Health Equity for Black People Impacted by Triple Negative Breast Cancer Resource Hub” grant to TOUCH, The Black Breast Cancer Alliance, the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida for their project Black TNBC Matters.
• In May 2023, The National Medical Products Administration has approved the supplemental new drug application (“sNDA”) for Shanghai Junshi Biosciences Co., Ltd.’s anti-PD-1 monoclonal antibody, toripalimab, which is used in conjunction with albumin-bound paclitaxel to treat PD-L1 p.
• In November 2022, The MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic TNBC patients was updated by Infinity Pharmaceutical
• Between 2012 and 2016, 12% of breast cancer diagnoses in the United States were triple-negative, with a 5-year survival rate that was 8% to 16% poorer than that of hormone receptor-positive illness
• In the year 2022, Germany had the most newly diagnosed incident instances of TNBC among the EU4 countries, accounting for almost 12,000 cases. France and Italy came in second and third, respectively
• In the US, approximately 10,000 instances of triple-negative breast cancer were in the advanced stage in 2022
• In 2022, Germany and Italy among the EU4 countries had the highest rates of TNBC cases in the advanced stages
• Future treatments like Hoffman-La Roche’s TECENTRIQ, Infinity Pharmaceuticals’ Eganelisib, GX-I7 + KEYTRUDA, and others might significantly increase the size of the TNBC market from 2019 through 2032
• Key Triple Negative Breast Cancer Companies: HiberCell, Hoffmann-La Roche, Infinity Pharma, CytoDyn, Valo Therapeutics, Medicenna, Jiangsu HengRui Medicine, G1 Therapeutics, BioLite Inc, Sanofi, X4 Pharmaceuticals, Phoenix Molecular Designs, and others
• Key Triple Negative Breast Cancer Therapies: Imprime PGG, Tecentriq, IPI-549 (Eganelisib), Leronlimab (PRO 140), PeptiCRAd-1, MDNA11, Camrelizumab, Trilaciclib, Odetiglucan, BLEX 404, Mavorixafor, PMD-026, and others
• The Triple Negative Breast Cancer epidemiology based on gender analyzed that Through various secondary domains it can be concluded that Triple Negative Breast Cancer affects females
• The Triple Negative Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Triple Negative Breast Cancer pipeline products will significantly revolutionize the Triple Negative Breast Cancer market dynamics.

Triple Negative Breast Cancer Overview

The term “triple negative breast cancer” (TNBC) refers to a tumour in which the hormones oestrogen and progesterone (ER/PR) are negative as determined by immunohistochemistry (IHC), and neither HER2 overexpression nor its gene amplification as determined by fluorescence in situ hybridization technique.

Get a Free sample for the Triple Negative Breast Cancer Market Report 

https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market

Triple Negative Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Triple Negative Breast Cancer Epidemiology Segmentation:

The Triple Negative Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Triple Negative Breast Cancer
• Prevalent Cases of Triple Negative Breast Cancer by severity
• Gender-specific Prevalence of Triple Negative Breast Cancer
• Diagnosed Cases of Episodic and Chronic Triple Negative Breast Cancer

Download the report to understand which factors are driving Triple Negative Breast Cancer epidemiology trends @ Triple Negative Breast Cancer Epidemiology Forecast

Triple Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Triple Negative Breast Cancer market or expected to get launched during the study period. The analysis covers Triple Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Triple Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Triple Negative Breast Cancer Therapies and Key Companies

• Imprime PGG: HiberCell
• Tecentriq: Hoffmann-La Roche
• IPI-549 (Eganelisib): Infinity Pharma
• Leronlimab (PRO 140): CytoDyn
• PeptiCRAd-1: Valo Therapeutics
• MDNA11: Medicenna
• Camrelizumab: Jiangsu HengRui Medicine
• Trilaciclib: G1 Therapeutics
• Odetiglucan: HiberCell
• BLEX 404: BioLite Inc
• Mavorixafor: Sanofi/X4 Pharmaceuticals
• PMD-026: Phoenix Molecular Designs

Discover more about therapies set to grab major Triple Negative Breast Cancer market share @ Triple Negative Breast Cancer Treatment Market

Triple Negative Breast Cancer Market Strengths

• Rise in TNBC market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radiotherapy techniques and novel systemic therapies.
• Improvement in genomics and proteomics can lead to an acceleration in the discovery of novel treatment and drug deliverance.

Triple Negative Breast Cancer Market Opportunities

• Increasing incidence trend will provide better therapeutic approaches for the TNBC market in the near future.
• The market of TNBC lacks an effective strategy to cure the condition, which provides a lucrative opportunity to develop more treatment options.
• Due to lack of competitors, there is a substantial market opportunity for key players to develop anaplastic tumour targeting therapies

Scope of the Triple Negative Breast Cancer Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Triple Negative Breast Cancer Companies: HiberCell, Hoffmann-La Roche, Infinity Pharma, CytoDyn, Valo Therapeutics, Medicenna, Jiangsu HengRui Medicine, G1 Therapeutics, BioLite Inc, Sanofi, X4 Pharmaceuticals, Phoenix Molecular Designs, and others
• Key Triple Negative Breast Cancer Therapies: Imprime PGG, Tecentriq, IPI-549 (Eganelisib), Leronlimab (PRO 140), PeptiCRAd-1, MDNA11, Camrelizumab, Trilaciclib, Odetiglucan, BLEX 404, Mavorixafor, PMD-026, and others
• Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
• Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Triple Negative Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Triple Negative Breast Cancer Market Access and Reimbursement 

To know more about Triple Negative Breast Cancer companies working in the treatment market, visit @ Triple Negative Breast Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Triple Negative Breast Cancer Market Report Introduction

2. Executive Summary for Triple Negative Breast Cancer

3. SWOT analysis of Triple Negative Breast Cancer

4. Triple Negative Breast Cancer Patient Share (%) Overview at a Glance

5. Triple Negative Breast Cancer Market Overview at a Glance

6. Triple Negative Breast Cancer Disease Background and Overview

7. Triple Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Triple Negative Breast Cancer 

9. Triple Negative Breast Cancer Current Treatment and Medical Practices

10. Triple Negative Breast Cancer Unmet Needs

11. Triple Negative Breast Cancer Emerging Therapies

12. Triple Negative Breast Cancer Market Outlook

13. Country-Wise Triple Negative Breast Cancer Market Analysis (2019–2032)

14. Triple Negative Breast Cancer Market Access and Reimbursement of Therapies

15. Triple Negative Breast Cancer Market Drivers

16. Triple Negative Breast Cancer Market Barriers

17.  Triple Negative Breast Cancer Appendix

18. Triple Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services